ResMed Inc. RMD
Set alert
As of Nov 2, 12:06 PM ET
- YTD
- -4.95%
- 1 year
- -7.26%
- Open
- 231.27
- Prev close
- 229.94
- Mkt cap
- 32.19B
- Vol
- 503.37K
- Avg vol
- 1.35M
- EPS
- 10.98
- P/E
- 20.85
- Div yield
- 1.04%
More statistics
- Low
- 227.73
- High
- 233.29
- Forward P/E
- 17.34
- Beta
- 0.75
- Short ratio
- 10.34
- Inst. own
- 73.30%
- Dividend
- 2.64
- Ex-div date
- Aug 19, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 231.77
- 200-d avg
- 225.03
- 1y target
- 251.52
3M chart
Events in this range
- Aug 6, 2026Earnings: 2.95; estimate 2.89; surprise 2.08%
- Aug 19, 2026Rating: Rothschild & Co · — → Neutral
- Aug 20, 2026Dividend: 0.66
- Aug 31, 2026Rating: Keybanc · Overweight → Overweight
- Sep 15, 2026Rating: RBC Capital · Sector Perform → Outperform
- Oct 29, 2026Earnings: 2.91; estimate 2.69; surprise 8.18%
- Oct 30, 2026Rating: Keybanc · Overweight → Overweight
- Oct 30, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 30, 2026Rating: RBC Capital · Outperform → Outperform
Signals (13)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 30, 2026 | 3 days ago |
| RSI: Overbought | Oct 20, 2026 | 1 week ago |
| RSI: Overbought | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
Key statistics
- Market cap
- 32.32B
- Enterprise value
- 35.83B
- Trailing P/E
- 22.03
- Forward P/E
- 17.34
- PEG ratio
- 1.35
- Price / sales
- 5.72
- Price / book
- 5.03
- EPS (TTM)
- 10.43
- Beta
- 0.75
- Dividend yield
- 1.04%
- Payout ratio
- 23.01%
- Profit margin
- 26.95%
- Revenue (TTM)
- 5.65B
- Revenue growth
- 8.60%
- Free cash flow
- 939.25M
- Total cash
- 1.47B
- Total debt
- 825.92M
- Return on equity
- 24.27%
- Shares outstanding
- 140.64M
- Short % of float
- 8.51%
- 50-day average
- 231.77
- 200-day average
- 225.03
Analyst view
Consensus: buy
- Target (low)
- 175.00
- Target (mean)
- 251.52
- Target (high)
- 320.00
- Strong buy2
- Buy7
- Hold10
- Sell1
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 3.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 3.02 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.69 | 2.91 | +0.22 | +8.18% |
| Aug 6, 2026 | Jun 30, 2026 | 2.89 | 2.95 | +0.06 | +2.08% |
| Apr 30, 2026 | Mar 31, 2026 | 2.80 | 2.86 | +0.06 | +2.14% |
| Jan 29, 2026 | Dec 31, 2025 | 2.74 | 2.81 | +0.07 | +2.55% |
| Oct 30, 2025 | Sep 30, 2025 | 2.51 | 2.55 | +0.04 | +1.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Keybanc | main | Overweight | Overweight |
| Sep 15, 2026 | RBC Capital | up | Sector Perform | Outperform |
| Aug 31, 2026 | Keybanc | main | Overweight | Overweight |
| Aug 19, 2026 | Rothschild & Co | init | — | Neutral |
About ResMed Inc.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- resmed.com
News
- ResMed: 3 Key Takeaways for Long-Term Investors
- Citigroup Maintains Neutral on ResMed, Raises Price Target to $270
- RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288
- Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250
- ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
- Keybanc Maintains Overweight on ResMed, Raises Price Target to $277
- RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
- What ResMed (RMD) Said on Its Q1 Earnings Call
- ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
- ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
Your note
Sign in to keep a note on RMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURT CAROL J | Director | Stock Award(Grant) | Nov 19, 2025 | 18,816 |
| FARRELL MICHAEL J | Chief Executive Officer | Sale | Sep 7, 2026 | 468,346 |
| FARRELL MICHAEL J. | Chief Executive Officer | Sale | Oct 6, 2026 | 481,893 |
| FARRELL PETER CRAIG | Director | Sale | Aug 4, 2026 | 52,773 |
| GHOSHAL KAUSHIK | Officer | Sale | Mar 9, 2025 | 19,353 |
| LEONG JUSTIN | Officer | Stock Award(Grant) | Aug 13, 2026 | 35,489 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.76% | 12,317,194 | 2.83B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.74% | 9,474,129 | 2.18B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.63% | 7,913,661 | 1.82B | Jun 29, 2026 |
| State Street Corporation | 4.75% | 6,680,735 | 1.54B | Jun 29, 2026 |
| Geode Capital Management, LLC | 3.09% | 4,352,320 | 1.00B | Jun 29, 2026 |
| Bank Of New York Mellon Corporation | 2.98% | 4,197,610 | 964.69M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27% | 4,605,309 | 1.06B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.67% | 3,758,092 | 863.68M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.23% | 3,143,005 | 722.33M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.37% | 1,922,453 | 441.82M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.34% | 1,882,957 | 432.74M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 1.33% | 1,866,016 | 428.85M | Jun 29, 2026 |